Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

被引:10
作者
Pan, Rui [1 ]
Cheng, Jinping [2 ]
Lai, Kelin [1 ]
Huang, Qing [3 ]
Wu, Hui [1 ]
Tang, Yamei [2 ]
机构
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金
国家重点研发计划;
关键词
Intracranial hemorrhage; Vitamin K antagonists; Prothrombin complex concentrate; Meta-analysis; FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; ANTICOAGULATION REVERSAL; WARFARIN; GUIDELINES; MANAGEMENT; COAGULOPATHY; ENLARGEMENT;
D O I
10.1007/s10072-019-3726-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 42 条
[11]   Admission to a neurologic/neurosurgical intensive cave unit is associated with reduced mortality rate after intracerebral hemorrhage [J].
Diringer, MN ;
Edwards, DF .
CRITICAL CARE MEDICINE, 2001, 29 (03) :635-640
[12]  
Edavettal M, 2014, AM SURGEON, V80, P372
[13]  
Fong WC, 2014, HONG KONG MED J, V20, P486, DOI 10.12809/hkmj144246
[14]   EMERGENCY REVERSAL OF ANTICOAGULATION AFTER INTRACEREBRAL HEMORRHAGE [J].
FREDRIKSSON, K ;
NORRVING, B ;
STROMBLAD, LG .
STROKE, 1992, 23 (07) :972-977
[15]   Reversal of Coagulopathy Using Prothrombin Complex Concentrates is Associated with Improved Outcome Compared to Fresh Frozen Plasma in Warfarin-Associated Intracranial Hemorrhage [J].
Frontera, Jennifer A. ;
Gordon, Errol ;
Zach, Victor ;
Jovine, Maximo ;
Uchino, Ken ;
Hussain, Muhammad S. ;
Aledort, Louis .
NEUROCRITICAL CARE, 2014, 21 (03) :397-406
[16]   Guidelines for the Management of Spontaneous Intracerebral Hemorrhage A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association [J].
Hemphill, J. Claude, III ;
Greenberg, Steven M. ;
Anderson, Craig S. ;
Becker, Kyra ;
Bendok, Bernard R. ;
Cushman, Mary ;
Fung, Gordon L. ;
Goldstein, Joshua N. ;
Macdonald, R. Loch ;
Mitchell, Pamela H. ;
Scott, Phillip A. ;
Selim, Magdy H. ;
Woo, Daniel .
STROKE, 2015, 46 (07) :2032-2060
[17]   Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose [J].
Holland, Lorne ;
Warkentin, Theodore E. ;
Refaai, Majed ;
Crowther, Mark A. ;
Johnston, Marilyn A. ;
Sarode, Ravindra .
TRANSFUSION, 2009, 49 (06) :1171-1177
[18]   Improved survival of patients with warfarin-associated intracerebral haemorrhage: a retrospective longitudinal population-based study [J].
Huhtakangas, Juha ;
Tetri, Sami ;
Juvela, Seppo ;
Saloheimo, Pertti ;
Bode, Michaela K. ;
Karttunen, Vesa ;
Kaeraejaemaeki, Anni ;
Hillbom, Matti .
INTERNATIONAL JOURNAL OF STROKE, 2015, 10 (06) :876-881
[19]   Guidelines on oral anticoagulation with warfarin - fourth edition [J].
Keeling, David ;
Baglin, Trevor ;
Tait, Campbell ;
Watson, Henry ;
Perry, David ;
Baglin, Caroline ;
Kitchen, Steve ;
Makris, Michael .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (03) :311-324
[20]   2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J].
Kirchhof, Paulus ;
Benussi, Stefano ;
Kotecha, Dipak ;
Ahlsson, Anders ;
Atar, Dan ;
Casadei, Barbara ;
Castella, Manuel ;
Diener, Hans-Christoph ;
Heidbuchel, Hein ;
Hendriks, Jeroen ;
Hindricks, Gerhard ;
Manolis, Antonis S. ;
Oldgren, Jonas ;
Popescu, Bogdan Alexandru ;
Schotten, Ulrich ;
Van Putte, Bart ;
Vardas, Panagiotis .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 50 (05) :E1-E88